Efficacy and safety of dutasteride with tadalafil add-on therapy in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia

Abstract Objective To evaluate the efficacy and safety of add-on therapy with the phosphodiesterase type 5 inhibitor tadalafil in Japanese men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with dutasteride. Results Twenty-four patients were enrolled. The...

Full description

Bibliographic Details

Published in:	BMC Research Notes
Main Authors:	Daisuke Gotoh, Kazumasa Torimoto, Yosuke Morizawa, Shunta Hori, Yasushi Nakai, Makito Miyake, Kiyohide Fujimoto
Format:	Article
Language:	English
Published:	BMC 2022-09-01
Subjects:	Dutasteride Phosphodiesterase type 5 inhibitor Tadalafil Benign prostatic hyperplasia
Online Access:	https://doi.org/10.1186/s13104-022-06183-0